Vifor Pharma Group
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vifor Pharma Group
Cara Therapeutics and licensee Vifor Pharma have released positive topline data from the KALM-2 study in chronic kidney disease patients with moderate-to-severe pruritus undergoing hemodialysis, using a first-in-class selective kappa opioid receptor agonist which does not enter the CNS.
The Swiss company has been talking up its therapy for elevated levels of potassium in the blood which contributed to strong sales growth for Vifor in 2019.
US biotech expands 2017 collaboration with Alnylam and inks collaboration with WuXi. Plus deals involving AbbVie, Allergan, Amazon, Thermo Fisher, Qiagen, Boehringer Ingelheim, Trutino, Taiho, Arcus, Eisai, Fuji Yakuhin, Hikma, Glenmark, Hanmi, GC, Bayer, GW.
Fresenius Kabi and Vifor Pharma have agreed to create a joint venture in China for intravenous iron products.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Vifor Pharma Management Ltd./ Subsidiaries: Aspreva Pharmaceuticals Corporation
- Galenica Group
- Relypsa, Inc.
- Vifor Pharma
- Vifor-Fresenius Medical Care Renal Pharma Ltd.
- OM Pharma